Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR2.16), EUR0.37 better than the analyst estimate of (EUR2.53). Revenue for the quarter came in at EUR47.4 million versus the consensus estimate of EUR37.37 million.

GUIDANCE:

Ascendis Pharma sees FY2023 revenue of EUR150-160 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.